Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (879)	4/18/2000 11:07:00 PM
From: david james	Respond to of 1298

Hi Bosco, Yes, absolutely. CEGE did not receive milestone payments from JT this quarter (although they should next quarter) so they will probably post a small loss from operations. I do think they will do better than the -32 cent estimate but CEGE may try to find a few charges to offset their big gain. The gain from the sale of assets could be as much $6/share. But consider the following. How many people look at CEGE's loss of 39 cents/share in 1999 and believe the company lost money from operations? quote.yahoo.com How many are aware that they would have posted a profit if not for the $15 mill one time charge (-50 cents/share) for cancelling the merger with Genzyme? Yes, the $6/share will be considered a one time gain, but right now CEGE is not getting fairly valued given their $20 in assets. Perception is important. And maybe this gain will help to get them some of the attention they need. Dave